[go: up one dir, main page]

EA201070193A1 - Лечение детских опухолей - Google Patents

Лечение детских опухолей

Info

Publication number
EA201070193A1
EA201070193A1 EA201070193A EA201070193A EA201070193A1 EA 201070193 A1 EA201070193 A1 EA 201070193A1 EA 201070193 A EA201070193 A EA 201070193A EA 201070193 A EA201070193 A EA 201070193A EA 201070193 A1 EA201070193 A1 EA 201070193A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tumors
children
treatment
pnet
neuroblastomas
Prior art date
Application number
EA201070193A
Other languages
English (en)
Other versions
EA015933B1 (ru
Inventor
Клаудио Пизано
Лоредана Веши
Паоло Карминати
Original Assignee
Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. filed Critical Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Publication of EA201070193A1 publication Critical patent/EA201070193A1/ru
Publication of EA015933B1 publication Critical patent/EA015933B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

В изобретении раскрыт подкласс производных камптотецина, применимых для получения лекарственного средства, предназначенного для лечения опухолей у детей, например рабдомиосаркомы, примитивных нейроэктодермальных опухолей (PNET) и нейробластомы.
EA201070193A 2007-08-01 2008-07-03 Лечение детских опухолей EA015933B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07113603 2007-08-01
PCT/EP2008/058601 WO2009015981A2 (en) 2007-08-01 2008-07-03 Treatment of pediatric tumors

Publications (2)

Publication Number Publication Date
EA201070193A1 true EA201070193A1 (ru) 2010-06-30
EA015933B1 EA015933B1 (ru) 2011-12-30

Family

ID=38799381

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070193A EA015933B1 (ru) 2007-08-01 2008-07-03 Лечение детских опухолей

Country Status (11)

Country Link
US (1) US8829021B2 (ru)
EP (1) EP2182951A2 (ru)
JP (2) JP5765937B2 (ru)
KR (1) KR20100051837A (ru)
CN (1) CN101784277A (ru)
BR (1) BRPI0815051A2 (ru)
CA (1) CA2694389C (ru)
EA (1) EA015933B1 (ru)
MX (1) MX2010001084A (ru)
SG (1) SG183010A1 (ru)
WO (1) WO2009015981A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014070767A1 (en) 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
CA2952771A1 (en) 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
JP2018507910A (ja) * 2015-02-12 2018-03-22 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ジ・ユニバーシティ・オブ・アリゾナ 神経芽細胞腫を治療する方法
BR112018008651A2 (pt) 2015-10-30 2018-10-30 Cancer Prevention Pharmaceuticals Inc formulação de combinação de dose fixa de eflornitina e sulindaco
JP2022532766A (ja) 2019-05-17 2022-07-19 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド 家族性腺腫性ポリポーシスを処置するための方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1044977E (pt) * 1999-03-09 2002-09-30 Sigma Tau Ind Farmaceuti Derivados de camptotecina com actividade antitumoral
SI1962850T1 (sl) 2005-12-21 2012-06-29 Sigma Tau Ind Farmaceuti Zdravljenje tumorjev, odpornih proti zdravilom
WO2008098701A1 (en) 2007-02-13 2008-08-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives

Also Published As

Publication number Publication date
WO2009015981A2 (en) 2009-02-05
SG183010A1 (en) 2012-08-30
CA2694389A1 (en) 2009-02-05
US8829021B2 (en) 2014-09-09
KR20100051837A (ko) 2010-05-18
WO2009015981A3 (en) 2009-09-03
AU2008282024A1 (en) 2009-02-05
EA015933B1 (ru) 2011-12-30
MX2010001084A (es) 2010-03-25
JP2014111653A (ja) 2014-06-19
JP2010534699A (ja) 2010-11-11
CN101784277A (zh) 2010-07-21
CA2694389C (en) 2016-01-19
US20100197718A1 (en) 2010-08-05
BRPI0815051A2 (pt) 2015-02-10
JP5765937B2 (ja) 2015-08-19
EP2182951A2 (en) 2010-05-12

Similar Documents

Publication Publication Date Title
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
TW200605870A (en) Topical methadone compositions and methods for using the same
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2006133707A3 (en) Anti-cancer combination treatment and kit-of-part
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
TW200734334A (en) Treatment of substance abuse
TW200606162A (en) Pyrazolopyridine derivatives
UA104988C2 (ru) Производные пирониндола и способ их получения
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
MXPA05004697A (es) Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
ATE549023T1 (de) Formulierungen mit jorumycin-, renieramycin-, safracin- oder saframycin-verwandten verbindungen und einen disaccharide zur behandlung von proliferativen erkrankungen
EA201070193A1 (ru) Лечение детских опухолей
WO2007130501A3 (en) Combination therapy for treatment of cancer
EP2161037A3 (en) Camptothecin-Somatostatin conjugates
HRP20080569T3 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
WO2006113718A3 (en) Compositions for the treatment of neoplasms
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
ATE536368T1 (de) Konjugate von zytotoxischen verbindungen mit peptiden
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU